Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Conference, Event, Product/Service, Survey

Vizgen Showcases Expansion of MERSCOPEtm In Situ Single-Cell Spatial Genomics Platform Capabilities at AGBT


Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced an expansion of its product roadmap and the availability of the Formalin-Fixed Paraffin-Embedded (FFPE) Human Immuno-oncology data release. Vizgen's product updates will expand sample input flexibility, propel new applications, and empower greater data insights. These updates demonstrate the company's continued commitment to exposing the research community to the power of spatial genomics. The updates will be presented as oral and poster presentations at the Advances in Genome Biology and Technology (AGBT) 2022 General Meeting, occurring June 6-9, 2022.

Product roadmap updates for 2H 2022:

The new publicly available FFPE Human Immuno-oncology dataset, generated with Vizgen's MERSCOPE platform, represents the largest public data set for single-cell spatial genomics ever released. This data was generated using Vizgen's forthcoming FFPE Sample Preparation Kit. The dataset contains 16 total datasets from 8 FFPE tumor tissue types including breast, colon, lung, liver, skin, prostate, uterine and ovarian, each measuring 500 genes totaling over 4 billion transcripts and 9 million cells cumulatively. The dataset is freely available to participants in the company's Data Release Program to use in any way and can be downloaded at https://info.vizgen.com/merscope-ffpe-solution.

"We announced MERSCOPE, the industry's first solution to combine single-cell and spatial transcriptomics in one turnkey system, and the only commercial platform solution for MERFISH technology, last year at AGBT. Customer adoption from academic research institutions and pharmaceutical companies has been tremendous and our platform continues to lead spatial genomics innovation in the industry," said Terry Lo, President and CEO of Vizgen. "With this first of its kind data release, the research community now has access to an unprecedented scale and quality of single-cell spatial genomics data from cancer samples. As we look to establish new standards in the field, we are excited about our upcoming roadmap of new capabilities that further our mission to improve human health."

AGBT Presentation Details

Date:

Tuesday, June 7, 1:30 p.m. ? 3:00 p.m. ET

Title:

In Situ Single-Cell Transcriptomic Imaging in Formalin-Fixed Paraffin-Embedded (FFPE) Tissues with MERSCOPE

Presented by:

Jiang He, Scientific Co-founder, Director of Scientific Affairs, Vizgen

Poster Number:

593

Location:

Bonnet Creek Ballroom Salon VII - XII

Date:

Wednesday, June 8, 8:10 p.m. ? 8:30 p.m. ET

Title:

Molecular atlassing with MERSCOPEtm: A new spatial transcriptomics technique accurately reveals the organization of the mouse brain transcriptome

Presented by:

George Emanuel, Scientific Co-founder, Director of Technology & Partnerships, Vizgen

Location:

Floridian Ballroom

Vizgen is also proud to sponsor the AGBT Women's Networking Event, taking place on June 7 from 5:30 ? 7:15 p.m. ET.

For additional information about Vizgen's Human FFPE Immuno-oncology Data Release, visit: https://vizgen.com/human-ffpe-immunooncology-release-roadmap/

About Vizgen

Vizgen is dedicated to pioneering the next generation of genomics, providing tools that demonstrate the possibilities of in situ single-cell spatial genomics, setting the standard for the spatial genomics field. These tools are enabling researchers to gain new insight into the biological systems that govern human health and disease with spatial context. The company's MERSCOPEtm Platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution. MERSCOPE provides transformative insight into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, cell and gene therapy, and is an essential tool for accelerating drug discovery and development. For more information, go to www.vizgen.com. Connect on social media Twitter, LinkedIn and Facebook.


These press releases may also interest you

at 20:50
Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D investment was RMB372 million, the cash and cash equivalent at the end of 2023 was...

at 20:48
Carrieverse Co., Ltd. has announced the grand opening of its Web3 metaverse game, 'Carrieverse', on the 28th of this month. It will be released in most regions around the world, and is expected to attract more than 1.2 million pre-registered users,...

at 20:45
The "Austria Social Commerce Market Intelligence and Future Growth Dynamics Databook - 50+ KPIs on Social Commerce Trends by End-Use Sectors, Operational KPIs, Retail Product Dynamics, and Consumer Demographics - Q1 2024 Update" report has been added...

at 20:35
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study of the combination of InnoCare's novel SHP2 (Src Homology 2 domain containing...

at 20:30
The "Argentina Conversational Commerce Market Intelligence and Future Growth Dynamics Databook - 75+ KPIs on Conversational Commerce Trends by End-Use Sectors, Operational KPIs, Product Offering, and Spend By Application - Q2 2023 Update" report has...

at 20:15
The "Brazil Conversational Commerce Market Intelligence and Future Growth Dynamics Databook - 75+ KPIs on Conversational Commerce Trends by End-Use Sectors, Operational KPIs, Product Offering, and Spend By Application - Q2 2023 Update" report has...



News published on and distributed by: